Lung cancer drug cocktail shows promise in delaying tumor growth

NCT ID NCT02759614

Completed Disease control Sponsor: Guangdong Association of Clinical Trials Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 study tested whether adding bevacizumab (Avastin) to erlotinib (Tarceva) works better than erlotinib alone for Chinese patients with advanced non-small cell lung cancer (NSCLC) that has specific EGFR mutations. Over 300 patients were randomly assigned to one of the two treatment groups. The main goal was to see how long the cancer stayed under control (progression-free survival).

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bevacizumab (Avastin) and erlotinib (Tarceva)
What this could lead to: If successful, this combination could offer a new first-line treatment option that delays cancer progression in patients with a specific type of lung cancer.
What could go wrong: This is a completed Phase 3 trial, but results may not apply to all lung cancer patients. Adding bevacizumab also increases the risk of side effects like high blood pressure or bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC

Contacts and locations

Locations

Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences

Guangzhou, Guangdong, 510080, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.